Status:
TERMINATED
Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression
Lead Sponsor:
Hillerod Hospital, Denmark
Collaborating Sponsors:
Wyeth is now a wholly owned subsidiary of Pfizer
Tvergaards Foundation
Conditions:
Major Depression
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.
Detailed Description
Antidepressant therapy has a delayed onset of action of 4-6 weeks. Pindolol has in some studies shown an accelerating effect. In this study we investigate the effect of 20 mg of pindolol retarded form...
Eligibility Criteria
Inclusion
- Major depression
Exclusion
- Allergy towards pindolol, venlafaxine or other tablet constituents
- Liver or kidney impairment
- Diabetics
- Age below 18 years
- Severe cardiac disease
- Asthma.
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00159146
Start Date
August 1 2002
End Date
September 1 2007
Last Update
December 27 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Psychiatric Research Unit, Hillerod Hospital
Hillerød, Denmark, 3400